By Editorial Staff
In a recent correspondence, Dr. Kelly Shanahan, President of METAvivor, offered a poignant reflection on the volatile nature of life while living with Metastatic Breast Cancer (MBC). Drawing a parallel between the sudden, unpredictable shifts in Tahoe’s spring weather and the rapid, often jarring trajectory of an MBC diagnosis, Dr. Shanahan’s message serves as both a personal update and a strategic roadmap for one of the most critical advocacy organizations in the field of oncology. As the scientific community prepares for a season of major conferences and regulatory milestones, the message from METAvivor is clear: the patient voice is no longer just a peripheral concern—it is a mandatory component of modern clinical research.
Main Facts: The State of Metastasis Research
The core mission of METAvivor remains centered on funding high-impact, peer-reviewed research for metastatic breast cancer. This year, the organization’s Scientific Advisory Board (SAB) faced an unprecedented surge in demand. METAvivor received 200 Letters of Intent (LOIs) during its current grant cycle—a figure that doubles the volume of previous years.
According to Dr. Shanahan, this surge is not necessarily an indication of an influx of new researchers, but rather a reflection of the profound uncertainty surrounding federal research funding. With traditional government grants becoming increasingly competitive and restrictive, independent organizations like METAvivor have become the lifeblood of laboratory progress. Dr. Stuart Martin, a long-time member of the SAB, noted that METAvivor’s efforts are pivotal in ensuring that metastasis research maintains momentum during a "challenging time" for the scientific community.
The selection process for these grants is rigorous. Following the review of LOIs, the organization will invite the most promising candidates to submit full applications. These will undergo a dual-layered evaluation process involving both scientific experts and Patient Advocate Reviewers (PARs), ensuring that every dollar allocated aligns with the practical, life-saving needs of the patient population.
Chronology of Upcoming Advocacy and Scientific Milestones
The coming weeks represent a "super-season" for oncology, characterized by a series of high-profile events where the patient experience will take center stage:
- Late May (Chicago): The American Society of Clinical Oncology (ASCO) annual meeting—the largest and most influential oncology conference in the world—serves as the primary venue for global updates.
- May 31, 2024: Dr. Shanahan is slated to deliver a 12-minute keynote on the main stage. Her presentation, "How to design trials that are meaningful to people with cancer," will tackle the essential need for patient-centered endpoints.
- Mid-June (Austin, Minnesota): Dr. Shanahan will travel to the Hormel Institute’s Global Cancer Consortium to present on the latest advances in metastasis research. Dr. Danny Welch, a seminal figure in the field and a METAvivor SAB member, will provide the keynote address on the "hallmarks of metastasis."
- Ongoing: The Live from Stage 4 podcast series continues to provide a vital platform for patient-led news, covering everything from complex regulatory discussions to symptom management.
Supporting Data: Regulatory Shifts and Drug Approvals
The landscape of MBC treatment is currently undergoing its most significant shift in years. The regulatory environment, specifically regarding how the FDA and international bodies evaluate new therapies, is becoming a focal point for advocacy groups.
The Camizestrant Controversy
A recent point of contention involves the FDA’s Oncologic Drugs Advisory Committee (ODAC) and their stance on the drug camizestrant. The debate centers on whether to allow a switch from a standard AI (Aromatase Inhibitor) + CDK4/6 inhibitor combination to an investigational regimen of camizestrant + a CDK4/6 inhibitor upon the detection of an ESR1 mutation, even before clinical imaging shows disease progression.
While the U.S. FDA has chosen to continue reviewing data, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has signaled a different path, recommending the approval of camizestrant based on the positive data from the SERENA-6 trial. This discrepancy highlights the complexity of international regulatory harmonization and the urgent need for new technologies to be incorporated into the decision-making process.
May 2024 FDA Approvals: A Wave of Progress
Despite regulatory friction, the pipeline is yielding tangible results for patients. In May alone, the FDA authorized:
- Vepdegestrant (Veppanu): A targeted therapy for ER+, HER2- MBC patients who harbor an ESR1 mutation.
- Datopotamab deruxtecan (Dato-DXd): Approved as a first-line treatment for patients with metastatic Triple-Negative Breast Cancer (TNBC) who are not eligible for immunotherapy.
- Enhertu (Trastuzumab deruxtecan): An expansion of indications into the early-stage HER2+ setting, aimed at reducing the risk of recurrence and progression to metastatic disease.
These approvals represent a critical victory for advocates who have long pushed for more specific, biomarker-driven treatment options.
Official Responses and the "Patient-Centered" Mandate
The overarching theme of Dr. Shanahan’s tenure is the "bigger table" philosophy. She argues that researchers must pull up a chair for patients—the true experts in living with the disease—when designing clinical trials.
"If you want to know what a patient wants, just ask us," Dr. Shanahan noted, channeling a bit of pop-culture wit by referencing the Spice Girls’ famous mantra, "Tell me what you want, what you really, really want."
This is not merely a rhetorical stance; it is a strategic requirement for trial success. When trials are designed with "patient-centered endpoints," they are more likely to achieve high enrollment, better adherence, and ultimately, more meaningful data. METAvivor is actively seeking both scientists and Patient Advocate Reviewers (PARs) to assist in this mission. The organization emphasizes that, beyond scientific expertise, financial support is the primary catalyst for these advancements, urging the public to contribute to ongoing research efforts.
Implications for the Future of MBC Care
The implications of these developments are twofold: scientific and societal.
Scientifically, the shift toward targeted therapies (like those addressing ESR1 mutations) suggests that the era of "one-size-fits-all" chemotherapy is rapidly fading. We are moving toward a precision-medicine model where the molecular profile of a tumor dictates the treatment path, allowing for longer progression-free survival and improved quality of life.
Societally, the increasing presence of patient advocates at the "big stages" of oncology conferences indicates a fundamental power shift. For decades, the doctor-patient relationship was largely paternalistic; today, the patient is a stakeholder in the development of their own cure. By engaging with podcasts like Live from Stage 4 and participating in grant reviews, patients are transforming from passive recipients of care into active architects of the research agenda.
Conclusion: A Personal and Collective Hope
As Dr. Shanahan prepares to take the stage at ASCO in Chicago and subsequently heads to Nashville for her own clinical trial scans, her journey mirrors that of the thousands she represents. The uncertainty of her own health—the "snow falling outside the office window"—is a shared reality for the MBC community.
However, the rapid succession of FDA approvals and the record-breaking number of research grant applications provide a bedrock of hope. The goal remains steadfast: to turn a terminal diagnosis into a manageable condition, and eventually, to secure a cure. For those interested in joining this fight, the path is clear: support the research, offer your voice as an advocate, and continue to demand that the medical establishment builds a table large enough for everyone.
As the medical community looks toward the remainder of the year, the collaborative spirit between researchers and the patients they serve will undoubtedly be the defining factor in the success of the next generation of cancer therapies.
About the Author
